Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Completed · Phase 2 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

The purpose of this study is to test the hypothesis that in patients with type 2 diabetes, the addition of exenatide will result in lower time-averaged serum glucose during a 24-hour period, compared with placebo.

Key facts

Study ID

NCT00241423

Run by

AstraZeneca

People needed

30

Starts

2005-10-01

Expected to finish

2007-06-01

Last updated by the study team

2015-02-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has an HbA1c between 7.0% and 10.0%, inclusive.
• Subject has a body mass index (BMI) >25 kg/m\^2 and <50 kg/m\^2.
• Subject is on a stable dose of metformin or metformin plus a thiazolidinedione.

You may not qualify if…

• Subject has been treated with any of the following medications: *exogenous insulin for more than 1 week within 3 months of screening, *sulfonylureas or meglitinides within 2 months of screening, *alpha-glucosidase inhibitors within 2 months of screening, *pramlintide acetate injection within 2 months of screening.
• Subject has received exenatide, GLP-1 analogs, DPP-IV inhibitors, or has participated in this study previously.

Where it is running

• Research Site — Washington D.C., District of Columbia, United States
• Research Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.